chronic hepatitis C
Effectiveness and tolerability of pegylated interferon alfa2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study
... Results Patient characteristics and disposition In total, 239 patients with chronic hepatitis C were screened by 64 physicians (internists and gastroenterolo- gists) at 46 centres in Belgium. Twenty ...
7
Cost-effectiveness model for sofosbuvir in chronic hepatitis C
... 3. Local expert opinion, 2013. 4. Gilead Phase III trials : NEUTRINO, FISSION, POSITRON, FUSION and VALENCE studies. 5. Janssen pharmaceutical companies of Johnson & Johnson. Telaprevir for the treatment of genotype ...
1
Plasma carnitine is associated with fatigue in chronic hepatitis C but not in irritable bowel syndrome
... For Peer Review Participants were systematically asked for fatigue and were convened to complete a self- reported measure pertaining to the psychological state (e.g. fatigue). Fatigue was measured using the French ...
30
IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C
... of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, ...
20
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma
... of chronic hepatitis C (CHC) patients the immune response fails to eradicate the virus due to impaired T cell and antibody responses, and little antiviral efficacy of IFN-stimulated genes (ISGs) ...of ...
14
Liver stiffness diminishes with antiviral response in chronic hepatitis C.: Liver Stiffness Kinetics on HCV Therapy
... Review Chronic infection with hepatitis C virus (HCV) is the leading cause of chronic liver disease in Europe and the United ...States. Chronic hepatitis C is responsible for ...
29
Long‐term clinical benefits of Sofosbuvir‐based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa
... with chronic hepatitis C in Central and West Africa Mael Baudoin, Maame Esi Woode, Marie Nishimwe, Maud Lemoine, Babacar Sylla, Charles Kouanfack, Raoul Moh, Moussa Seydi, Nicolas Rouveau, ...
25
Chronic hepatitis C virus infection, a new cardiovascular risk factor?
... A retrospective study from the Taiwan National Health Insurance Program included 3,113 subjects with a newly detected HCV infection and 12,452 age- and gender-matched subjects without HCV infection followed up to 5 years ...
20
Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence”
... for hepatitis C virus (HCV) infection, it is well established that many other organ systems are affected, increasing the overall burden of dis- ease [ 1 – 3 ...of chronic HCV across 354 clinical studies in ...
6
Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
... CV is a small-vessel systemic vasculitis, and organ damage results from circulation and precipitation of cryoglobulins and complement activation. A wide range of clinical symptoms can be observed during CV, and ...
12
Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis
... A random effect model performed on results from two studies shows the effect of SVR achievement in reducing the presence of fatigue at follow-up: OR 0.52 [95%CI 0.29; 0.93] (Appendix 12A). A second analysis was performed ...
31
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.
... IFN-α, IFN-λ Thymosin α1 TLR7, TLR9 agonists Lipoviral particle ApoB ApoC ApoE Cell-cell trans- mission Apo Apo Apo Apo Apo Replication HTAs: Antisense miR122 HMGCoA inhibitors Cycloph[r] ...
4
Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.
... Methods Only articles, abstracts and posters in English were selected. An indexed MEDLINE search was conducted concurrently from January 2007 until December 2015 by the medical head of hepatology department and a ...
25
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
... of chronic HCV and advanced liver-related diseases and its treatment, consistent with the current understanding of the biology of chronic HCV-related liver disease and its treatment ...
18
Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)
... Tangui Barré, Marie Libérée Nishimwe, Camelia Protopopescu, Fabienne Marcellin, Fabrice Carrat, Céline Dorival, Elisabeth Delarocque-Astagneau,. Dominique G[r] ...
44
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
... Due to these limitations, we aimed to perform an improved systematic review, focusing on direct compar- isons between the four most frequently used, discussed and recommended tests, 3, 4, 24, 25 at least for CHC since ...
15
Extrahepatic manifestations of chronic hepatitis C virus infection
... arterial hypertension. Early serum complement component (C1q, C4) are very low. Chronic renal insufficiency may develop in 10-20% of HCV-Cryovas patients. Renal morphological features are characterized by ...
19
View of New treatments for chronic hepatitis C virus infection
... of hepatitis C virus (HCV) infection by the combination of pegylated interferon and ribavirin has been the standard of care since 1998 and has helped to achieve a sustained virologic response (SVR) in more than ...
10
Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.: NK cells in chronic hepatitis C and hepatitis B
... and viral load in HCV and HBV patients. To pin point this correlation, we observed that the viral load was correlated negatively with CD3 - CD56 dim NKG2A + cells subset. Taking in account that i) CD56 + NKG2A + cells ...
13
Hepatitis C virus-related vasculitis
... MC: chronic hepatitis C virus (HCV) infection and other infections, autoimmune diseases [connective tissue diseases (CTD)], and B cell lymphoproliferative disorders ...
19